September 7, 2005
The OASIS-5/MICHELANGELO study, presented today at the European Society of Cardiology meeting in Stockholm, Sweden, showed that fondaparinux, a new anti-thrombotic therapy, was as effective as enoxaparin in preventing heart attacks, death and ischemia (reduction in blood supply to the tissues) at nine days after an event but demonstrated a dramatic reduction in major bleeding. The study indicated patients had a lower mortality rate at the one-month mark after an acute coronary event.
Hamilton, ON (September 5, 2005) -- A Canadian-led study involving researchers from 41 countries has demonstrated in the world's largest study of acute coronary syndromes (ACS) that a new anti-thrombotic therapy is safer and as effective as the traditional therapy used in preventing heart attacks, death and ischemia in people with serious heart conditions.
The above story is based on materials provided by McMaster University. Note: Materials may be edited for content and length.
Cite This Page:
McMaster University. "New Anti-thrombotic Therapy Effective, Safer For Patients." ScienceDaily. ScienceDaily, 7 September 2005. <www.sciencedaily.com/releases/2005/09/050906074328.htm>.
McMaster University. (2005, September 7). New Anti-thrombotic Therapy Effective, Safer For Patients. ScienceDaily. Retrieved March 8, 2014 from www.sciencedaily.com/releases/2005/09/050906074328.htm
McMaster University. "New Anti-thrombotic Therapy Effective, Safer For Patients." ScienceDaily. www.sciencedaily.com/releases/2005/09/050906074328.htm (accessed March 8, 2014).